Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067066 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01067066: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01067066 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01067066, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.
Interventions
- DRUG Temodar (Temozolomide)
- DRUG TPI 287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-02-03 |
| Est. Completion | 2016-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067066
The ClinicalTrials.gov registry entry for NCT01067066 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temodar (Temozolomide) is the first listed.
NCT01067066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067066 about?
NCT01067066 is a clinical study titled "A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma". The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolo...
What is the current status of trial NCT01067066?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-02-03. Estimated completion is 2016-07-06.
What interventions are being tested in trial NCT01067066?
The interventions under investigation include: Temodar (Temozolomide) (DRUG), TPI 287 (DRUG).
Who is sponsoring clinical trial NCT01067066?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.